The measurement of pessimism: The Hopelessness Scale.

Beck, Aaron T.; Weissman, Arlene; Lester, David; Trexler, Larry D.

doi:10.1037/h0037562

Cited by 4,704 publications

(3,301 citation statements)

References 11 publications

Supporting

Mentioning

2,968

Contrasting

Unclassified

188

Order By: Relevance

“…Patients' subjective perception of depression severity was assessed by means of self-report with the Beck Depression Inventory (BDI) (Beck et al, 1961). Hopelessness was assessed with the Beck Hopelessness Scale (BHS) (Beck et al, 1974). The level of psychosocial functioning was assessed with the Global Assessment Scale (GAS) (excluding the suicide item) (Endicott et al, 1976).…”

Section: Methodsmentioning

confidence: 99%

The role of moral objections to suicide in the assessment of suicidal patients

Lizardi

Dervic

Grunebaum

et al. 2008

Journal of Psychiatric Research

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

The role of moral objections to suicide in the assessment of suicidal patients

Lizardi

Dervic

Grunebaum

et al. 2008

Journal of Psychiatric Research

View full text Add to dashboard Cite

show abstract

“…Abbey et al, 2006;Beck et al, 1974;Nissim et al, 2010) ? (Abbey et al, 2006;Beck et al, 1974;Nissim et al, 2010) + (Northouse et al, 2007) Continued Spiritual suffering in the cancer context …”

Section: Mini-suffering State Examination (Msse)mentioning

confidence: 99%

Assessment of spiritual suffering in the cancer context: A systematic literature review

et al. 2014

View full text Add to dashboard Cite

Objective: An important goal of cancer medicine is relief of patients' suffering. In view of the clinical challenges of identifying suffering patients, we sought to identify valid instruments for assessing the spiritual suffering of people diagnosed with cancer.Method: A systematic review of the literature was conducted in the Medline, Embase, the Cochrane Library, and PsycINFO databases seeking assessment instruments that measure either suffering or one of its synonyms or symptoms. The psychometric properties of the identified measures were compared.Results: A total of 90 articles were identified that supplied information about 58 measures. The constructs examined were: suffering, hopelessness/demoralization, hope, meaning, spiritual well-being, quality of life where a spiritual/existential dimension was included, distress in the palliative care setting and pain, distress or struggle of a spiritual nature. The Pictorial Representation of Illness and Self Measure (PRISM) (patient completed) was the most promising measure identified for measuring the burden of suffering caused by illness due to its ease of use and the inclusion of a subjective component.Significance of Results: Although the appropriateness of any measure for the assessment of spiritual suffering in cancer patients will depend on the context in which it is intended to be utilized, the PRISM is promising for measuring the burden of suffering due to illness.

show abstract

“…Pre-treatment assessments encompassed depression severity (Hamilton Rating Scale for Depression, HRSD-17; Hamilton, 1967), suicidal ideation (HRSD-17 item 3) hopelessness (Beck Hopelessness Scale;Beck et al, 1974), anxiety severity (Hamilton Rating Scale for Anxiety; Hamilton, 1959), cognitive functioning (Mattis, 1988), co-existing medical illness burden (Cumulative Illness Rating Scale for Geriatrics, CIRS-G; Miller et al, 1992), disability and health-related quality of life (Quality of Well-Being Scale, Bush et al, 1982; MOS-Short Form; Ware and Sherbourne, 1992), and social support/self-esteem (Interpersonal Support Evaluation List, ISEL; Cohen et al, 1985).…”

Section: Assessmentmentioning

confidence: 99%

Predicting 6‐week treatment response to escitalopram pharmacotherapy in late‐life major depressive disorder

Saghafi

Brown

Butters

et al. 2007

Int J Geriat Psychiatry

View full text Add to dashboard Cite

SUMMARYObjective-Approximately half of older patients treated for major depressive disorder (MDD) do not achieve symptomatic remission and functional recovery with first-line pharmacotherapy. This study aims to characterize sociodemographic, clinical, and neuropsychologic correlates of full, partial, and non-response to escitalopram monotherapy of unipolar MDD in later life.Methods-One hundred and seventy-five patients aged 60 and older were assessed at baseline on demographic variables, depression severity, hopelessness, anxiety, cognitive functioning, coexisting medical illness burden, social support, and quality of life (disability). Subjects received 10 mg/d of open-label escitalopram and were divided into full (n =55; 31%), partial (n =75; 42.9%), and non-responder (n =45; 25.7%) groups based on Hamilton depression scores at week 6. Univariate followed by multivariate analyses tested for differences between the three groups.Results-Non-responders to treatment were found to be more severely depressed and anxious at baseline than both full and partial responders, more disabled, and with lower self-esteem than full responders. In general partial responders resembled full responders more than they resembled nonresponders. In multivariate models, more severe anxiety symptoms (both psychological and somatic) and lower self-esteem predicted worse response status at 6 weeks.Conclusion-Among treatment-seeking elderly persons with MDD, higher anxiety symptoms and lower self-esteem predict poorer response after six weeks of escitalopram treatment.

show abstract

The measurement of pessimism: The Hopelessness Scale.

Cited by 4,704 publications

References 11 publications

The role of moral objections to suicide in the assessment of suicidal patients

The role of moral objections to suicide in the assessment of suicidal patients

Assessment of spiritual suffering in the cancer context: A systematic literature review

Predicting 6‐week treatment response to escitalopram pharmacotherapy in late‐life major depressive disorder

Contact Info

Product

Resources

About